Clinical Trial Update: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) [Phase 2, Phase 3]

View source ↗

Summary

EyeBiotech's MK-8748 (EYE201) is in a Phase 2/3 trial for macular degeneration, including age-related macular degeneration, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYE201/MK-8748 (MK-8748)

Snippet

Sponsor: EyeBiotech Ltd. | Conditions: Macular Degeneration, Age-Related Macular Degeneration | Phase 2, Phase 3 | Status: RECRUITING